Regulatory Writing with Closed-Loop Gen-AI that Protects IP and Saves Time, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how closed-loop Gen-AI is transforming regulatory writing through secure, efficient automation. Attendees will understand the need for closed-loop AI in regulatory writing. The featured speaker will discuss the need for Gen-AI that is specifically “blended” for regulatory writing. Attendees will experience the automation possible through Gen-AI tools.

TORONTO, Oct. 16, 2025 /PRNewswire/ — Many regulatory writers are facing increased pressure to produce safety narratives, clinical study reports (CSRs) and other critical documents quickly, often relying on manual copy-paste methods that cause delays and elevate risks. Join this webinar to examine the limitations of traditional workflows and explore how secure, closed-loop generative AI (Gen-AI) can improve both speed and consistency in regulatory writing while safeguarding proprietary information.

The featured speaker will frankly discuss the risks associated with open Gen-AI systems, particularly around data exposure, and will highlight the benefits of closed-loop solutions designed specifically for regulatory writing teams. Attendees will gain a clear understanding of how blended AI systems enhance document generation accuracy, how automation can be applied to CSRs and narrative development and how these tools can significantly reduce manual effort and approval timelines.

Register for this webinar to learn how closed-loop Gen-AI is transforming regulatory writing through secure, efficient automation.

Join Mark Pittman, Chief Revenue Officer, ZYLIQ, for the live webinar on Monday, November 3, 2025, at 2pm EST (7pm CET/EU-Central).

For more information, or to register for this event, visit Regulatory Writing with Closed-Loop Gen-AI that Protects IP and Saves Time.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regulatory-writing-with-closed-loop-gen-ai-that-protects-ip-and-saves-time-upcoming-webinar-hosted-by-xtalks-302585868.html

SOURCE Xtalks

Staff

Recent Posts

TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering

Integrated smart technology builds on TempraMed's proven VIVI platform, providing robust Temperature control with medication…

41 minutes ago

More Than a Meal Plan: The Clinical Impact of a Kidney Dietitian

NORTHAMPTON, MA / ACCESS Newswire / December 26, 2025 / Specialized nutrition experts are key…

3 hours ago

President Trump’s Executive Marijuana Action Exposes the Truth-How the DEA Delayed Medicine While Protecting Everything Else

"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within…

3 hours ago

From Follower to Force: China’s Biotech Sector Enters the Global Clinical Mainstream

WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…

6 hours ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…

9 hours ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…

9 hours ago